Alaunos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Alaunos Therapeutics, Inc. (TCRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 127.03% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-08-14
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-09-30 was 127.03%.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-06-30 was 95.36%, a 14.93% increase year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-03-31 was 95.63%, a 25.38% increase year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2022-09-30 was 85.89%, a 17.92% increase year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2025 was 127.03%, a 25.50% decline from fiscal 2024.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 170.50%, a 52.07% increase from fiscal 2023.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 112.12%, a 26.33% increase from fiscal 2022.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 88.75%, a 18.65% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 127.03% 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | 127.03% 10-Q · filed 2025-11-14 | 127.03% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 125.11% 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | 170.50% 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | 170.50% 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | 170.50% 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | 112.12% 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 95.63% 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 95.36% 10-Q · filed 2023-08-14 | 95.63% 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | 95.63% 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 88.75% 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | 85.89% 10-Q · filed 2023-11-14 | 85.89% 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 82.97% 10-Q · filed 2023-08-14 | 82.97% 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | 76.27% 10-Q · filed 2023-05-10 | ||||
| 2021-12-31 | 74.80% 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | 72.84% 10-Q · filed 2022-11-14 | 74.80% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 74.80% 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | 74.20% 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | 74.41% 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | 74.18% 10-Q · filed 2021-11-08 | 74.18% 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | 73.90% 10-Q · filed 2021-08-13 | 73.74% 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | 74.18% 10-Q · filed 2021-05-06 | 73.01% 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | 85.00% 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | 78.34% 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | 78.85% 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | 85.00% 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | 84.71% 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | 83.08% 10-Q · filed 2019-11-07 | ||||
| 2018-06-30 | 81.66% 10-Q · filed 2019-08-08 | ||||
| 2018-03-31 | 81.10% 10-Q · filed 2019-05-08 | ||||
| 2017-12-31 | 81.03% 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | 80.95% 10-Q · filed 2018-11-09 | ||||
| 2017-06-30 | 81.03% 10-Q · filed 2018-08-08 | ||||
| 2017-03-31 | 80.90% 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | 82.95% 10-K · filed 2019-03-05 | ||||
| 2016-09-30 | 79.34% 10-Q · filed 2017-11-06 | 79.34% 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | 80.81% 10-Q · filed 2017-07-31 | ||||
| 2016-03-31 | 79.69% 10-Q · filed 2017-05-01 | ||||
| 2015-12-31 | 86.81% 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | 81.70% 10-Q · filed 2016-11-09 | ||||
| 2015-03-31 | 86.81% 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | 94.55% 10-K · filed 2017-02-16 | ||||
| 2014-03-31 | 94.55% 10-Q · filed 2015-05-07 | ||||
| 2013-12-31 | 95.96% 10-K · filed 2016-02-24 | ||||
| 2013-09-30 | 95.64% 10-Q · filed 2014-10-30 | ||||
| 2013-03-31 | 83.69% 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | 83.53% 10-K · filed 2015-02-26 | ||||
| 2012-09-30 | 83.51% 10-Q · filed 2013-10-22 | ||||
| 2012-06-30 | 83.52% 10-Q · filed 2013-08-08 | ||||
| 2012-03-31 | 83.53% 10-Q · filed 2013-05-07 | ||||
| 2011-12-31 | 87.29% 10-K · filed 2014-03-03 | ||||
| 2011-09-30 | 87.40% 10-Q · filed 2012-11-08 | ||||
| 2011-06-30 | 87.40% 10-Q/A · filed 2012-08-28 | ||||
| 2010-12-31 | 90.60% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |